<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703026</url>
  </required_header>
  <id_info>
    <org_study_id>CTC0900328</org_study_id>
    <nct_id>NCT01703026</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses</brief_title>
  <official_title>Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to&#xD;
      detect pancreatic cancer at an earlier stage, to improve current method of T staging and&#xD;
      assessment of surgical resectability and also to distinguish between benign and malignant&#xD;
      pancreatic masses. All these will translate into better clinical outcome, and also avoid&#xD;
      unnecessary surgery in situations of unresectable cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">33</enrollment>
  <condition>Pancreatic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 50 subjects will be enrolled. The study population will be drawn from patients&#xD;
        referred for EUS evaluation on basis of suspected pancreatic cancer. These patients could&#xD;
        be either from clinics or from the hospital wards.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients over a 1-year period referred for EUS examination due to&#xD;
             suspected pancreatic lesions will be enrolled.&#xD;
&#xD;
          -  Age 21 years and above.&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with clinical conditions that preclude the use of DEFINITY™ will be excluded.&#xD;
        These conditions are:&#xD;
&#xD;
          -  Right-to-left, bi-directional, or transient right-to-left cardiac shunts;&#xD;
&#xD;
          -  Worsening or clinically unstable congestive heart failure;&#xD;
&#xD;
          -  Acute myocardial infarction or acute coronary syndromes;&#xD;
&#xD;
          -  Serious ventricular arrhythmias or high risk for arrhythmias due to prolongation of&#xD;
             the QT interval;&#xD;
&#xD;
          -  Respiratory failure;&#xD;
&#xD;
          -  Severe emphysema, pulmonary emboli or other conditions that cause pulmonary&#xD;
             hypertension due to compromised pulmonary arterial vasculature;&#xD;
&#xD;
          -  Hypersensitivity to DEFINITY™ or its components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007 Aug 15;110(4):738-44.</citation>
    <PMID>17580363</PMID>
  </reference>
  <reference>
    <citation>Ang TL. Endoscopic ultrasound: moving from diagnostics to therapeutics. J Dig Dis. 2008 Aug;9(3):117-28. Review.</citation>
    <PMID>18956589</PMID>
  </reference>
  <reference>
    <citation>Snady H, Cooperman A, Siegel J. Endoscopic ultrasonography compared with computed tomography with ERCP in patients with obstructive jaundice or small peri-pancreatic mass. Gastrointest Endosc. 1992 Jan-Feb;38(1):27-34.</citation>
    <PMID>1612375</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 5, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

